key: cord-0775453-7lwr1b0u
authors: Wagner, A.; Guzek, A.; Ruff, J.; Jasinska, J.; Scheikl, U.; Zwazl, I.; Kundi, M.; Stockinger, H.; Farcet, M. R.; Kreil, T.; Hoeltl, E.; Wiedermann, U.
title: A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms
date: 2020-12-22
journal: nan
DOI: 10.1101/2020.12.22.20248604
sha: f06f80a6c74e381ed119ce19a95b04efb51393ad
doc_id: 775453
cord_uid: 7lwr1b0u

Background In spring 2020, at the beginning of the first pandemic severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) wave in Europe, we set up an assay system for large-scale testing of virus-specific and protective antibodies including their longevity. Methods We analysed the sera of 1655 adult employees for SARS-CoV-2-specific antibodies using the S1 subunit of the spike protein of SARS-CoV-2. Sera containing S1-reactive antibodies were further evaluated for receptor-binding domain (RBD)- and nucleocapsid protein (NCP)-specific antibodies in relation to the neutralisation test (NT) results at 0, three and six months. Findings We found immunoglobulin G (IgG) and/or IgA antibodies reactive to the S1 protein in 10.15% (n=168) of the participants. In total, 0.97% (n=16) were positive for S1-IgG, 0.91% (n=15) were S1-IgG- borderline and 8.28% (n=137) exhibited only S1-IgA antibodies. Next, we evaluated the 168 S1-reactive sera for RBD- and NCP specificity: 8.33% (n=14) had detectable RBD-specific and 6.55% (n=11) NCP-specific antibodies. The latter correlated with NTs (kappa coefficient = 0.8660) but started to decline already after 3 months. RBD-specific antibodies correlated best with the NT (kappa = 0.9448) and only these antibodies were stable for up to six months. All participants with virus-neutralising antibodies reported symptoms, of which, anosmia and/or dysgeusia correlated best with the detection of virus-neutralising antibodies. Interpretation RBD-specific antibodies were most reliably detected post infection, independent of the number/severity of symptoms, and correlated best with protective neutralising antibodies at least for six months. They thus qualify best for large-scale seroepidemiological evaluation of both seroprevalence and seroprotection.

The ongoing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has led to dramatic restrictions in public life worldwide to mitigate the anticipated epidemic peak. 1 At the early stage of the pandemic, data were missing to estimate the actual number of infected individuals, including asymptomatic/oligosymptomatic cases that were left unreported due to the limitations in the polymerase chain reaction (PCR) testing capacity and strategy that was initially confined to the fulfilment of case definitions. It was, therefore, difficult to assess the actual risk of infection for employers with respect to shared workspaces and staff in contact with customers. Where possible, employers facilitated employees´ work in home office mode with the intention to reduce the number of social contacts and consequently, the risk of infection. 2 In order to estimate past infections irrespective of symptoms and a preceding PCR test, specific and sensitive serological antibody tests, including neutralising assays, are necessary tools. 3 Additionally, serological tests are an important instrument for epidemiological surveillance and to assess whether/when herd immunity has been reached within a population.

Several validated serological formats are now in use, based on enzyme-linked immunosorbent assays (ELISA) and chemiluminescence targeting different SARS-CoV-2 antigens. 4 The target antigens are the spike (S) protein with its receptor-binding domain (RBD), and the nucleocapsid protein (NCP). Both antigens have been shown to induce robust antibody responses in infected individuals. 5, 6 Another important question has emerged as to whether the detected antibodies also indicate protection against reinfection. In this regard, testing for neutralising antibodies is considered to be the gold standard as it additionally assesses antibody functionality, i.e. virus inactivation. 6 However, such testing is laborious, time-consuming and requires biosafety level three laboratory space, and therefore not suitable for large-scale testing/seroprevalence surveys. Along these lines, it is still unclear which test would prove most appropriate to describe transmission patterns and to determine immunity upon virus contact in overall as well as in defined populations (in contrast to individual analysis/neutralisation tests [NTs] ).

With the beginning of an exponential increase in coronavirus disease 2019 (COVID-19) cases in Austria, the government declared a public lockdown with March 16 th , 2020. At this time, the actual rate of infections was unknown and consequently, the risk of virus exposure for personnel in various work settings.

The goal of the current study was to analyse the seroprevalence of SARS-CoV-2-specific antibodies at the beginning of the pandemic and over several months in a representative cohort of employees from a large Austrian company. Besides, the evaluation of seroprotection and persistence of protective antibodies were /critical aspects of this study for which several assays were included to identify the most accurate test for large-scale seroepidemiological analysis. The participants were included irrespective of a previous history of COVID-19 or experienced symptoms. Already before study onset, the employees were split into two groups, those sent into home office and those remaining on-site. The accumulated basic demographic data (gender, age, household size) and information on respiratory tract infections and symptoms, medical risk factors and travel history were analysed in context with the SARS-CoV-2-specific antibody test All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020. 12.22.20248604 doi: medRxiv preprint results. Employees with virus-reactive antibodies at the initial blood draw were invited for follow-up blood draws at three and six months after study onset to analyse the persistence of the detected antibody levels. At six months, also participants without detectable virus-reactive antibodies at the initial blood draw were asked for a follow-up blood draw in order to detect seroconversion and to assess the development of seroprevalence in the overall study population over the last months.

We included 1655 serum samples of employees working for a large company in Vienna. While half of the staff continuously worked on-site with frequent client contacts, the other half worked from home at the beginning of this trial followed by a weekly rotation between home office and on-site work after the lockdown period in Austria. The blood samples were taken at the medical centre of the company between 2 nd and 17 th April 2020 and sent in for further analysis (to the Institute of Specific Prophylaxis and Tropical Medicine at the Medical University of Vienna. The employees gave informed consent to SARS-CoV-2 serological testing and answered a questionnaire covering demographic data and their medical history, including current medications (see Supplement materials). The ethics committee of the Medical University of Vienna approved this monocentric study (EK 1438/2020, EK 1746/2020).

The SARS-CoV-2 specific antibody levels were measured with four different serological assays. After determining S1-specific IgG and IgA by ELISA, we further analysed those presenting positive or borderline results for RBD-and NCP-specific antibodies and by a live virus neutralisation test (at Takeda´s Global Pathogen Safety unit in Vienna) (for detailed information see supplementary materials).

Data were evaluated for the two groups (working on-site and from home) and the subgroups stratified for age (15 to 25 years, 25 to 50 and above the age of 50). Seropositivity as a dependent variable was evaluated in a general linear model for binominal counts (see supplementary materials for more details).

Overall, the study population consisted of 1655 volunteers, with an almost balanced female/male ratio (53.53%/46.47%) (table 1, suppl. figure 1) . The majority of the study population (62.30%) was in the medium-age group (25-50 years) . Higher percentages of the medium-age and older age groups (53.83% and 62.78%, respectively) had been sent home to All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020. 12.22.20248604 doi: medRxiv preprint work in contrast to only 27.88% of the young age group. In relative terms, 52.33% of the total study population worked from home. Less than half of the participants (42.05%) reported that they had experienced symptoms compatible with COVID-19 within the last three months before the beginning of the study, with cough, rhinitis, sore throat, and fever being most frequently mentioned (suppl. figure 2a). One quarter (23.63%) had risk factors in their medical history, which potentially predisposed for a severe COVID-19 disease (suppl. figure 2b ). However, 145 (8.76%) did not give details about the type of risk factors. Furthermore, 24.35% reported regular medication uptake (table 1, suppl. figure 3 ).

Serological testing for SARS-CoV-2 S1-specific IgG and IgA antibodies revealed that 1487 participants (89.85%) were seronegative (figure 1a). Thus, 10.15% displayed S1-reactive antibodies, among whom 16 (9.52%) were IgG-positive, 15 (893%) IgG-borderline, and 137 (81.55%) exhibited only IgA antibodies without IgG antibodies.

Further description of participants with antibodies reactive to S1 showed that COVID-19associated symptoms were recorded in 39.88% of the participants with and in 42.17% without S1-reactive antibodies (figures 1b and c). With respect to the working situation, the highest rate of S1-positive or -borderline participants was home office workers before and during the beginning of the study (figure 1d). Regarding age, the highest number of participants with virusreactive antibodies were between 25 and 50 years old (medium-age group) (n=111, 6.71% of all participants) (figure 1e).

The statistical analysis of the demographic and medical data revealed that three factors significantly correlated with S1 seropositivity (table 2), i.e. (i) age, decreasing seropositivity with increasing age, (ii) home office, and (iii) loss of taste and/or smell. Concerning symptoms, anosmia/dysgeusia showed the highest probability for a positive virus (S1)-specific antibody result (odds ratio 22.48), whereas the presence of any other reported symptom did not.

To further characterise antibody responses, all 168 sera with detectable S1-specific antibodies were also tested for RBD-and NCP-specific antibodies. Only a part of the S1-reactive sera also displayed RBD-or NCP-specific antibodies: 8.33% (14/168) had detectable RBD-specific total antibodies, whereas ten of these sera were also positive for S1-specific IgG, with two IgG borderlines and two IgG negatives (figure 2). The NCP-specific antibodies were positive in 6.55% (11/168) of the respondents with S1-reactive antibodies, with seven also being IgGpositive, one IgG-borderline and two IgG negatives. Of the S1-IgA-positive or -borderline samples, two were positive for RBD and two for NCP (one of these for both).

Virus-neutralising antibodies are regarded as surrogate of protection. For detection of these functional antibodies within the group of S1-positive sera, the NT, regarded as the gold standard among the SARS-CoV-2-specific serological assays, was performed. The results revealed that ten out of 16 S1-IgG-positive, two out of nine S1-IgG-borderline and only one of the S1-IgA positive/borderline sera were also positive in the NT (figure 2, suppl. figure 5).

We then analysed whether the antibodies directed against the various SARS-CoV-2 antigens, such as S1, RBD or NCP, correlated with the presence of neutralising/protective antibodies. All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.22.20248604 doi: medRxiv preprint

The RBD-specific antibodies showed the highest agreement with the NTtotal antibodies, kappa (k)=0.94; p<0.0001 and IgM (k=0.89; p<0.0001) (figure 3), indicating that these RBDspecific antibodies can be used as a predictor/surrogate for antibodies with protective properties. By contrast, S1-specific IgA failed to show any correlation with the neutralising antibody levels. Furthermore, the quantity (antibody level) of S1-specific IgG and IgA was not predictive for a positive NT result (suppl. figure 5a and b ).

All participants with neutralising antibodies reported symptoms, albeit of different qualities and quantities (figure 4a). The most prominent symptom recorded by 69.23% of the NT-positive participants was anosmia/dysgeusia (figure 4b). However, the number of symptoms did not correlate with the level of the neutralisation titre (figure 4c). Of notice was that even in those with risk factors and neutralising antibodies, indicating past infection, neither a severe course of disease nor hospitalisation was reported. Regarding age distribution, the highest number of NT-positive test results was found in those aged 25 to 50 years, with slightly more males affected (53.85%) (figure 4d and e).

We were highly interested in exploring the longevity of robust seropositivity, i.e. detection of protective/neutralising antibodies, in our study population. Therefore, all participants with detectable virus-reactive antibody levels (n=168) were invited for further blood draws after three and six months. Again, antibodies binding to S1, RBD, and NCP were measured. Only the RBD-specific total antibody levels, which highly correlated with the neutralising antibodies, showed stable persistence, indicating that protective antibodies maintained for at least six months (figure 5). RBD-specific IgM was lost in 53.33% at already three months and remained relatively stable thereafter. In contrast, S1-specific IgG and IgA antibody levels, which may indicate virus contact but not necessarily protection, rather tended to decline within three months in 37.5% and 53.68% of the participants, respectively (figure 5). Nevertheless, when S1-specific IgG antibodies were detectable at three months, they further persisted in 90% of the cases (9/10), also up to six months. NCP-specific IgG was lost in 9.09% at three months, whereas 55.55% of NCP-specific IgG were lost at six months. Measurements of the total NCPspecific antibodies confirmed the result of the NCP-specific IgG assay and also showed that the antibodies remained positive for three months (figure 5).

At six months, all participants were invited again to assess how seroprevalence evolved. In total, we could evaluate antibody levels from 78.07% (1292/1655) volunteers, showing a nonsignificantly increased ratio of newly positives to those that became negative (chi² McNemar p=0.212) for S1-reactive IgG (table 3) . The prevalence of S1-reactive IgA antibodies decreased (p > 0.001) compared to the initial blood draw. RBD IgM antibody positivity as well as NCP IgG positivity increased over the six month period, although about 50% of previously positives became negative. With regard to the RBD-specific total antibodies none of the previously positive antibodies declined to negative concentrations, while 2.1% of the previously negative became positive. This increase in RBD seropositivity as well as the stability of these antibodies over a period of six months is expressed as ratio > 54 (table 3) .

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

In our longitudinal study, we aimed to evaluate the seroprevalence, seroprotection, and duration of immunity against SARS-CoV-2 in a representative cohort of 1655 working adults over at least six months. An important aspect was to investigate which serological assay with respect to antigen specificity would be most appropriate for large-scale screening of past infections and seroprotection. Furthermore, we intended to investigate whether specific symptoms may serve as prediction markers of seropositivity and whether specific demographic parameters or working circumstances influenced the likelihood of virus contact/infection. Finally, we also aimed to explore the duration of antibody responses and seroprotection up to six months.

Our study population comprised of three age groups ranging from 16 to 65 years representative of the Austrian adult working population. For age, logistic regression analysis showed that the likelihood of seropositivity decreased with age. At the initial blood draw, antibody screening was performed using one of the first tests on the market, a S1-specific ELISA. Of all participants, 10.15% had IgG and/or IgA antibodies (above the cut-off, including borderline values) with 9.52% of these being positive for S1-specific IgG. These results correspond to those of a preceding Austrian study, in which 1544 random PCR samples were tested between the 1 st and the 6 th of April 2020, showing that the maximum prevalence of infected individuals was 0.33% (upper 95% confidence interval value). 7 Our results of S1-specific IgG antibodies being prevalent in 0.97% of all participants would refer to the accumulated number of cases until that time. Similar rates have been reported for population-based seroprevalence studies in other European countries, while the rates have increased over time and varied substantially (0.4% to 14%) within different geographical regions relating to the occurrence of major infection clusters. 8, 9 At the beginning of the pandemic and throughout the Austrian pre-lockdown period, the employer facilitated home office work for the majority of their employees, particularly those of higher age and with potential risk factors for severe COVID-19. A certain number of employees, mainly the younger individuals, continued to work on-site during the overall study period, presumably exposing them to a higher risk of viral infection than those working from home. It could be due to this fact that the majority of the youngest group of 15-to 25-year-old employees, therefore, had the highest contact rates with colleagues or costumers, as this age group showed the highest levels of seropositivity. The percentage of S1-specific antibodies was lowest in the oldest age group, possibly explained by adequate compliance with the recommended hygiene measures and contact restrictions. Surprisingly, a higher prevalence of S1-specific antibodies was found in the group of participants working from home despite correction for age. However, this observation may in part be attributed to a bias related to the company´s policy that all employees with respiratory symptoms should stay at home.

Evaluation of the recent medical histories revealed that 42% of all participants had experienced respiratory symptoms, such as cough, fever, sore throat, and rhinitis. Concurrent circulation of other respiratory infections during winter and early spring could explain the fact that only some of them had detectable antibodies against S1 (9.91%). Notably, while the overall appearance of All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.22.20248604 doi: medRxiv preprint symptoms did not correlate with seropositivity, anosmia, or dysgeusia can be regarded as predictive markers for infection with SARS-CoV-2 and subsequent seropositivity.

On the other hand, the relatively low number of S1 antibodies in relation to the recorded symptoms may be ascribed to a fast waning of this antibody type, as was recently described by other authors. 10 Furthermore, it was previously reported that approx. 10% of (non-hospitalised) patients presenting with mild COVID-19 did not mount detectable S1 antibody responses. 11, 12 Thus, as we do not have PCR results from all our participants with recorded symptoms, some mild infections may have been missed in our study as well.

The improvement of the antibody test systems enabled detection of antibodies directed against different antigenic regions, such as the RBD and the NCP. Recent studies have indicated that the severity of symptoms/disease has an impact on antibody levels and possibly also on their specificities. 5, [11] [12] [13] Along these lines, we tested the antibody responses for these additional SARS-CoV-2 antigens within the group of participants, who had been identified as S1seropositive. Only 15.5% of the sera from participants with S1-specific antibodies also displayed antibodies directed against RBD or NCP. Notably, S1-specific IgA ratios, even at high levels, did not correspond with RBD-and NCP-specific antibody levels. This may be because the specificity of this test varies between 73% 14,15 and 94%, resulting in a very low estimated positive predictive value of approx. 39% according to Gereuts van Kessel et al. 16 The low specificity of SARS-CoV-2-specific IgA detection may be due to unspecific binding or cross-reactions of antibodies with other respiratory viruses. 14 Additionally, the role of serum IgA in COVID-19 disease is not yet clear. The very high IgA titres may still follow contact with the virus and could represent the mucosal activity of dimeric IgAhowever, this needs to be further confirmed. 12 Thus, the overall lower specificity of both IgA and IgG antibodies against S1, as reviewed recently, 17 also suggests that S1-specific antibody ELISA is not the optimal test for seroepidemiological surveys in low-prevalence settings (<5%) due to the reduced positive predictive value. 4, 18 Importantly, we wanted to test whether the antibodies measured were also associated with protection. In this respect, neutralising antibodies are regarded as surrogate marker of protection. 19 According to an experimental model with macaques, neutralising antibodies against SARS-CoV-2 may play an essential role in protection against reinfection. 20 In our study, the total RBD antibodies showed the highest correlation (kappa = 0.9448) with the neutralising antibodies of a live virus assay. Our data are supported by a recent study indicating that virus neutralisation is linked to B cell epitopes of the S protein, in particular neutralising epitopes of its RBD. 21, 22 In contrast to approx. 19% of S1-positive but asymptomatic participants, all of the participants with neutralising antibodies also showed symptomseven if some had only one or two mild symptoms of which anosmia or dysgeusia was the most prevalent. Thus, anosmia or dysgeusia may even be regarded as a highly reliable diagnostic marker in very mild cases, as also proposed by other colleagues. 23, 24 Of note, we could not find a correlation between the number of symptoms (implying severity) and the level of the neutralisation titre as supported by other recently published data. 25, 26 Our data further indicate that in individuals with anosmia/dysgeusia as a sole symptom, the quality and quantity of neutralising/protective antibodies does not differ compared to those with several reported and typical COVID-19 symptoms (fever, cough, dyspnoea). Thus, our observation does not confirm suggestions that All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.22.20248604 doi: medRxiv preprint people with mild symptoms do not develop robust protective/neutralising antibody responses. 5, 27 Of major importance is the duration of protective immune responses. A recent study in COVID-19 patients and patient contacts showed that S1-specific and neutralising antibodies could last for up to five months. 28 In contrast, a study in healthcare workers, though in a rather small cohort, postulated that the virus-specific antibody responses to the S antigen are only of short duration, in particular in individuals with mild or asymptomatic courses of disease. 29 By analogy with the study authored by Patel et al., the results of our investigation indicate that a high percentage of the S1-specific IgG and IgA antibodies declined already after three months. Similarly, the NCP-specific antibodies also started to decline after three months. The drop in S1-specific antibodies was most evident and may be explained by an asymptomatic or oligosymptomatic course of the disease. Of interest, we here show that the kinetics of antibody decline differed according to antibody specificity over time. While the S1-specific antibodies decreased mostly within the first months, the NCP-specific IgG was solidly detectable for three months and thereafter declined until up to six months. In total contrast, the RBD-specific antibodies, correlating with the protective/neutralising antibodies, were consistently stable up to six months, and the number/severity of symptoms did not affect the duration of seroprotection. These results in mind, testing for RBD-specific antibodies should deliver the most reliable results to determine seroprevalence up to several months after infection. In contrast, cases may be lost already after three months when evaluating S1-or NCP-specific antibody response. Considering data from the previous SARS-CoV-1 pandemic, during which neutralising antibodies remained detectable in most patients for two years, it can be assumed that the protective/neutralising antibodies will persist over the next months. 30 With the observation time of six months, we can also analyse changes in seroprevalence. Our results of the total study population show that in addition to the 0.85% RBD-positive participants at the initial blood draw, 2% additionally became positive after 6 months, thus reflecting the recorded increase in cases in Austria during the autumn of 2020. Further evaluation covering up to one year is planned.

In summary, we report a low seroprevalence of 0.97% with regard to S1-specific IgG antibody levels within the adult population at the early beginning of the pandemic. However, for immunity and protection, i.e. detection of neutralising/protective antibodies, the percentage is even lower with 0.85%. Importantly, these protective antibodies last for at least six months irrespective of a mild/oligosymptomatic or polysymptomatic course of the disease. Of all clinical symptoms, anosmia/dysgeusia was the most reliable symptom which was also associated with the generation of robust neutralising antibodies. In contrast, respiratory symptoms were not reliable diagnostic markers to predict antibodies or protection in the total study population. Large-scale seroprevalence studies can benefit from the use of a screening test with high SARS-CoV-2 specificity, as shown, RBD-specific assays could reliably detect SARS-CoV-2 specific antibodies for at least six months. Eventually, positive results may be retested with an appropriate neutralisation test to confirm the protective capacity of these antibodies.

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ; https://doi.org/10.1101/2020.12.22.20248604 doi: medRxiv preprint Figure 1 . S1-reactive IgA and IgG antibody results presented as proportions of the total study population (a), of those without (b) and with detectable S1-reactive antibodies (c) dependent whether symptoms were recorded, according to workplace (d), and age group (e). Antibodies were measured in sera from the initial blood draw at day 0. Figure 5 . Development of individual antibody results at three different time points (day 0 (n=168), at three (n=152) and six months (n=139)) measured against different SARS-CoV-2 antigen specificities (S1, RBD and NCP) in the subgroup of those with detectable S1-reactive antibodies at the first blood draw. Each line represents one participant, red lines represents a positive result, violet a borderline result and negative results in green.

Public Health Interventions for COVID-19: Emerging Evidence and Implications for an Evolving Public Health Crisis

Considerations for public health and social measures in the workplace in the context of COVID-19

Assessing the extent of SARS-CoV-2 circulation through serological studies

Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward

SARS-CoV-2 immunity: review and applications to phase 3 vaccine candidates

Immunology of COVID-19: Current State of the Science

Spread of SARS-CoV-2 in Austria -PCR tests in a representative sample SORA Institute for Social Research and Consulting

Prevalence of SARS-CoV-2 in Spain (ENE-COVID): a nationwide, population-based seroepidemiological study

Seroprevalence of anti-SARS-CoV-2 IgG antibodies in

SEROCoV-POP): a population-based study

SARS-CoV-2-Specific Antibody Detection for Seroepidemiology: A Multiplex Analysis Approach Accounting for Accurate Seroprevalence

Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients

Severe Acute Respiratory Syndrome Coronavirus 2-Specific Antibody Responses in Coronavirus Disease Patients

Evaluation of commercial and automated SARS-CoV-2 IgG and IgA ELISAs using coronavirus disease (COVID-19) patient samples

Performance of Severe Acute Respiratory Syndrome Coronavirus 2 Antibody Assays in Different Stages of Infection: Comparison of Commercial Enzyme-Linked Immunosorbent Assays and Rapid Tests

An evaluation of COVID-19 serological assays informs future diagnostics and exposure assessment

Review of Current Advances in Serologic Testing for COVID-19

Antibody Testing for COVID-19

A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation

SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Two linear epitopes on the SARS-CoV-2 spike protein that elicit neutralising antibodies in COVID-19 patients

Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation

Self-reported symptoms from exposure to Covid-19 provide support to clinical diagnosis, triage and prognosis: An exploratory analysis

Can symptoms of anosmia and dysgeusia be diagnostic for COVID-19?

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

Virological assessment of hospitalized patients with COVID-2019

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Robust neutralizing antibodies to SARS-CoV-2 infection persist for months

Change in Antibodies to SARS-CoV-2 Over 60

Days Among Health Care Personnel in

Duration of serum neutralizing antibodies for SARS-CoV-2: Lessons from SARS-CoV infection

All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted December 22, 2020. ;  https://doi.org/10.1101/2020. 12.22.20248604 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 100  142  17  59  101  143  18  60  102  144  19  61  103  145  20  62  104  146  21  63  105  147  22  64  106  148  23  65  107  149  24  66  108  150  25  67  109  151  26  68  110  152  27  69  111  153  28  70  112  154  29  71  113  155  30  72  114  156  31  73  115  157  32  74  116  158  33  75  117  159  34  76  118  160  35  77  119  161  36  78  120  162  37  79  121  163  38  80  122  164  39  81  123  165  40  82  124  166  41  83  125  167  42  84  126  168   NCP  S1 RBD NCP S1 RBD NCP S1 RBD NCP S1 RBD